In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 549-551

  Roblin, Patricia M ^a   Hammerschlag, Margaret R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; GATIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DRUG EFFICACY; HEP 2 CELL; HUMAN; MINIMUM INHIBITORY CONCENTRATION;

ANTI-INFECTIVE AGENTS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0032836326     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.549     Document Type: Article

References (10)

1. CDC. (1998). 1998 Guidelines for the treatment of sexually transmitted diseases. Centers for Disease Control. Morbidity and Mortality Weekly Report 47, RR-1, 1-111..
2. Block, S., Hedrick, J., Hammerschlag, M. R., Cassell, G. H. & Craft, J. C. (1995). Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin versus erythromycin ethylsuccinate. Pediatric Infectious Diseases Journal 14, 471-7.
3. Grayston, J. T., Campbell, L. A., Kuo, C.-C., Mordhorst, C. H., Saikku, P., Thom, D. H. et al. (1990). A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. Journal of Infectious Diseases 161, 618-25.
4. Hammerschlag, M. R., Hyman, C. L. & Roblin, P. M. (1992). In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 36, 682-3.
5. Hammerschlag, M. R. (1994). Antimicrobial susceptibility and therapy of infections due to Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1873-8.
6. Hammerschlag, M. R. (1999). Activity of quinolones against Chlamydia pneumoniae. Drugs, in press.
7. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. (1994). In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1402-3.
8. Miyashita, N., Niki, Y., Kishimoto, T., Nakajima, M. & Matsushima, T. (1997). In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrobial Agents and Chemotherapy 41, 1331-4.
9. Wise, R., Brenwald, N. P., Andrews, J. M. & Boswell, F. (1997). The activity of the methylpiperazinyl fluoroquinolone CG 5501 : a comparison with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 39, 447-52.
10. Nakashima, M., Uematsu, T., Kosuge, K., Kusajima, H., Ooie, T., Masuda, Y. et al. (1995). Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents and Chemotherapy 39, 2635-40.